GLIPR1 and gastric adenocarcinoma: Given that STAD patients with high expression of GLIPR1 showed worse survival, our results further demonstrated that GLIRP1 down-regulation by shRNA in gastric cancer increased cytotoxicity and cytokine production of both conventional CAR-T and CAR-ss-T cells in vitro and better tumor control in vivo, suggesting CAR-T cell therapy together with GLIRP1 knockdown of gastric cancer cells was a promising combination to increase efficacy.